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Abstract 
Background: As the number of long-term survivors of solid cancers keeps increasing, risk assessment of 
secondary hematologic malignancies is important for the prognosis of the patient. Germline genetic 
predisposition to secondary hematologic malignancy has been studied widely in myeloid neoplasms and 
rarely in lymphoid neoplasms. This study aimed to profile the mutational spectrums of patients with 
subsequent lymphoid tissue neoplasm to shed some light on the understudied area. 
Methods: In total, 39 patients who had primary solid cancer and subsequent hematologic malignancies 
were enrolled. We performed two next-generation sequencing (NGS) panel tests encompassing 
hereditary cancer predisposition genes and genes related to clonal hematopoiesis of indeterminate 
potential (CHIP). All statistical analyses were performed using R 3.5.1. 
Results: We found 8 of 39 patients with germline mutations in cancer predisposition genes; 4 of 18 
patients had therapy-related myeloid neoplasms (22.2%); and 4 of 15 patients had secondary lymphoid 
malignancies (26.7%). Notably, of 14 patients who initially suffered from thyroid cancer, 5 patients (35.7%) 
had germline mutations. Malignancy of lymphoid tissue showed no association with radioactive iodine 
therapy but was observed to a greater extent in germline mutation-positive thyroid cancer patients 
regardless of their history of treatment. We observed that 24 of 39 patients (61.5%) were CHIP carriers. 
Patients who had secondary lymphoid malignancy were less likely to have CHIP than those who had 
myeloid malignancy. 
Conclusions: In patients with primary solid cancer who are planning to undergo cytotoxic 
chemotherapy, radiotherapy, or radioactive iodine therapy, an initial assessment with germline mutation 
testing using an expanded NGS panel, including low, moderate, and high-risk cancer-associated genes, and 
somatic CHIP mutation testing can screen the patients who are at risk of developing therapy-related 
myeloid and lymphoid malignancies. Through careful screening and monitoring throughout the treatment 
process, patients can benefit from the early detection of secondary malignancies and receive proper 
treatment. 
Key words: hematologic malignancy; germline predisposition to cancer; clonal hematopoiesis of indeterminate 









Therapy-related hematologic malignancies occur 
in patients exposed to cytotoxic chemotherapy and/or 
radiation therapy. Studies on the genetic spectrums of 
therapy-related myeloid neoplasms (t-MNs) have 
revealed several associated genetic abnormalities that 
can be categorized as follows: i) chromosomal 
abnormalities in hematopoietic stem cells [1], ii) 
genetic mutations in tumor suppressor genes, 
oncogenes, genes that regulate cell proliferation or 
DNA methylations such as TP53, TET2, DNMT3A, 
and RUNX1, and RAS family genes [2, 3], iii) clonal 
hematopoiesis of indeterminate potential (CHIP) 
among hematopoietic stem cells [4-6], and iv) 
inherited mutations in cancer predisposition genes 
[7]. While identifying somatic abnormalities in 
malignant cells is essential for predicting the 
prognosis, relapse, and survival of the patients [8, 9], 
testing for inherited mutations in cancer 
predisposition genes is important for risk assessment 
in some patient groups, such as patients with a 
familial history of cancer or cancer patients who are 
recommended to undergo cytotoxic chemotherapy or 
radiation therapy. 
In the studies concerning germline genetic 
predisposition to hematologic malignancy, inherited 
mutations in high-penetrance cancer predisposition 
genes have been identified and well described [7]. 
Moderate or low-penetrance genes have been recently 
studied, where some cases indicated that inherited 
mutations in rather low-risk genes can be associated 
with susceptibility to t-MN [2]. For instance, WRN- 
mutated Werner’s syndrome patients have a 10% 
incidence of developing cancer and increased risk of 
acute leukemia [10]. Moreover, therapy-related 
myelodysplastic syndrome (MDS) has been reported 
in patients with Werner’s syndrome along with 
thyroid cancer who were exposed to radioactive 
iodine therapy [11]. While the genetic spectrum of 
t-MN has been widely studied and reviewed [3, 12], 
the genetic study of therapy-related lymphoid 
malignancy has rarely been carried out. As long-term 
survivors of solid cancers keep increasing, secondary 
lymphoid malignancies, which arise in relatively the 
latter part of the disease-free period [13], should be 
recognized, and their risk factors should be assessed. 
A recent study of lymphoid malignancy patients with 
familial traits showed 52% comorbidities with 
multiple types of solid cancers and found several 
pathogenic mutations in cancer predisposition genes 
[14]. In this regard, we hypothesized that an increased 
risk of secondary lymphoid malignancies after 
chemotherapy or radiation therapy can be explained 
by germline mutations in cancer predisposition genes. 
Hence, in the current study, we enrolled patients with 
hematologic malignancies, either from myeloid or 
lymphoid origins, who previously had solid tumors 
and tested them for germline mutations using an 
expanded next-generation sequencing (NGS) panel 
that included low-, moderate-, and high-risk 
cancer-associated genes. Considering the paucity of 
genetic studies concerning germline predisposition to 
secondary lymphoid malignancy, profiling the 
mutational spectrums of subsequent lymphoid tissue 
neoplasm patients in this study could provide novel 
insights for the better management of cancer patients. 
Methods 
The study subjects were enrolled retrospectively. 
We reviewed the bone marrow aspiration reports of 
852 patients from January 2013 to April 2018 at one 
university hospital. Via screening, 46 patients 
diagnosed with myeloid or lymphoid malignancies 
with previous histories of solid tumors were selected. 
Finally, 39 patients were enrolled for analyses, after 
excluding patients with insufficient preserved bone 
marrow samples at research specimen banking. All 
samples used in the analysis of CHIP were collected at 
the diagnosis with subsequent hematologic 
malignancies. To distinguish germline mutation from 
somatic mutation, we used follow-up bone marrow 
samples at the time of complete remission or 
peripheral blood samples with low or no blast 
observed. This study was approved by the Gangnam 
Severance Hospital Institutional Review Board (IRB 
approval number: 2018-0316-01). Detailed 
information on the targeted NGS panel sequencing 
and statistical analyses are described in 
Supplementary Document 1 and Supplementary 
Tables 1-2. 
Results 
The characteristics of the patients are described 
in Table 1. The median age of the participants at the 
time of initial cancer diagnosis was 61 years (Q1Q3; 
51.0, 68.5), and the median follow-up time was 7 
months (Q1Q3; 3.5, 36.0). The most common primary 
solid cancer was thyroid cancer (35.9%, 14/39), 
followed by breast cancer (12.8%, 5/39) and colorectal 
cancer (10.3%, 4/39). Twenty-four patients had a 
subsequent hematologic malignancy after being 
diagnosed with the primary cancer; acute myeloid 
leukemia (AML) in 7 cases, MDS in 11 cases, and 
myeloproliferative neoplasm (MPN) in 6 cases. Fifteen 
patients had secondary malignancy in lymphoid 
tissue; eight patients had diffuse large B-cell 
lymphoma (DLBCL), five patients had plasma cell 
myeloma (PCM), and two patients had chronic 
lymphocytic leukemia (Supplementary Table 3). 
Twenty-six patients (66.7%) received chemotherapy 




or radiotherapy as treatment for the initial solid 
cancer. Of 12 patients who had undergone 
chemotherapy, 4 were treated with alkylating agents 
and 2 with topoisomerase II inhibitors 
(Supplementary Table 3). 
 
Table 1. Patient characteristics of the study population 







Age (year)     
Median  
[interquartile range] 
61 [51.0;68.5] 63.5[57.0;68.5] 58.0[50.0;68.5] 0.338 
Sex     
Female 21 (53.8%) 6 (75.0%) 15 (48.4%) 0.343 
Male 18 (46.2%) 2 (25.0%) 16 (51.6%)  
Type of primary solid tumor    
Thyroid cancer 14 (35.9%) 5 (62.5%) 9 (29.0%) 0.227a 
Breast cancer 5 (12.8%) 0 (0.0%) 5 (16.1%)  
Colorectal cancer 4 (10.3%) 0 (0.0%) 4 (12.9%)  
Other* 16 (41.0%) 3 (37.5%) 13 (41.9%)  
Secondary malignancy    
Hematopoietic 24 (61.5%) 4 (50.0%) 20 (64.5%) 0.73 
Lymphoid 15 (38.5%) 4 (50.0%) 11 (35.5%)  
Type of hematologic malignancy    
AML 7 (17.9%) 2 (25.0%) 5 (16.1%) 0.53 
MDS 11 (28.2%) 2 (25.0%) 9 (29.0%)  
MPN 6 (15.4%) 0 (0.0%) 6 (19.4%)  
Mature B-cell 
neoplasm 
15 (38.5%) 4 (50.0%) 11 (35.5%)  
Treatmentb     
Radiotherapy 20 (51.3%) 5 (62.5%) 15 (48.4%) 0.753 
Chemotherapy 12 (30.8%) 2 (25.0%) 10 (32.3%) 1.000 
Disease-free survival 
(months) 




6 (15.4%) 1 (12.5%) 5 (16.1%) 1.000 
Overall survival 
(months) 
7.0 [3.5;36.0] 8.0 [ 1.0;46.0] 7.0 [ 4.5;29.0] 0.958 
Death 9 (23.1%) 9 (23.1%) 7 (22.6%) 1.000 
*: ovarian cancer, prostate cancer, lung cancer, common bile duct cancer, thymoma, 
hepatic cell carcinoma, gastric cancer, bladder cancer, esophageal cancer. 
a P values represent a comparison of germline-positive/germline negative across all 
types of primary solid tumor categories. 
b The total number of patients with radiotherapy or chemotherapy is 26. Six patients 
had both radiotherapy and chemotherapy. 
Abbreviations: AML: acute myeloid leukemia, MDS: myelodysplastic syndrome, 
MPN: myeloproliferative neoplasm. 
 
 
Detailed mutational findings of all participants 
are described in Figure 1. In total, 8 out of 39 patients 
had germline mutations in cancer predisposition 
genes [4 of 18 patients with t-MN (22.2%) and 4 of 15 
patients with secondary lymphoid malignancy 
(26.7%)]. Besides the pathogenic variants in the TP53 
gene, responsible for the Li-Fraumeni Syndrome, the 
rest of the pathogenic mutations that were found in 
BARD1, LZTR1, MUTYH, FANCD2, WRN, and 
RAD50 are moderate-risk alleles. One patient who 
suffered from ovarian cancer and breast cancer with 
therapy-related MDS (t-MDS) had germline 
mutations in BARD1 and MUTYH. The patient was 
first diagnosed with ovarian cancer at the age of 75, 
which is compatible with the moderate penetrance 
that the putative disease-causing gene has. 
Karyotyping of bone marrow when diagnosed with 
t-MDS showed monosomy 5 and monosomy 7, 
explained by the use of chemotherapy with alkylating 
agents and radiotherapy. The monoallelic 
(heterozygous) MUTYH mutation (NM_001128425.1: 
c.934-2A>G) found in the patient above was also 
detected in two other patients in this study group. 
Three patients who had the same MUTYH splicing 
mutation were first diagnosed with ovarian cancer, 
thymoma, and thyroid cancer, respectively. Two 
patients with thymoma and thyroid cancer 
underwent only surgical resection of the tumor. They 
had subsequent MDS and DLBCL. One patient out of 
the 18 t-MN patients (5.6%) had a germline mutation 
in the FANCD2 gene (NM_033084.3: c.757C>T, 
p.Arg253*). A nonsense germline mutation in RAD50 
(NM_005732.3: c.1106C>G, p.Ser369*) was observed 
in one patient in our study. The patient was first 
diagnosed with thyroid cancer; after surgical removal, 
the patient underwent radioactive iodine therapy 
(RAIT) and was diagnosed with PCM 68 months later. 
 
Table 2. Patients’ demographic data in the primary thyroid cancer 
group (n=14) 
RAIT (n=10) Surgery only (n=4) P value 
Female (n)   
7 4 0.607 
Age at diagnosis (mean ± SD)   
47.9 ± 11.9 53.5 ± 9.5 0.420 
Age at secondary malignancies (mean ± SD)   
52.1 ± 12.0 59.0 ± 9.6 0.329 
Myeloid malignancy   
7 0 0.076 
Type of secondary malignancies   
AML (4) DLBCL (3)  
MDS (1) PCM (1)  
CML (2)   
DLBCL (1)   
PCM (2)   
CHIP positive (n)   
6 1 0.554 
Germline positive (n)   
3 2 0.930 
Survival (months)   
32.0 ± 24.0 15.5 ± 15.6 0.233 
Abbreviations: AML: acute myeloid leukemia, CHIP: clonal hematopoiesis of 
indeterminate potential, CML: chronic myelogenous leukemia, DLBCL: diffuse 
large B-cell lymphoma, MDS: myelodysplastic syndrome, PCM: plasma cell 
myeloma, RAIT: radioactive iodine therapy, SD: standard deviation. 
 
 
Notably, out of the 14 patients who initially 
suffered from thyroid cancer, 5 patients (35.7%) had 
germline mutations. Malignancy of lymphoid tissue 
showed no association with RAIT but was observed to 
a greater extent in germline mutation-positive thyroid 
cancer patients regardless of their RAIT status (Figure 
1). The results of our study show that RAIT is 




associated with secondary myeloid malignancies with 
borderline statistical significance (P value = 0.076, 
Table 2). Unlike the previous study with CHIP 
analysis where the average age at the initial diagnosis 
of thyroid cancer was around 64 [15], the average age 




Figure 1. Summary of germline mutations and clonal hematopoiesis of indeterminate potential (CHIP) mutations. These mutations were observed in 39 cancer patients 
according to the subsequent hematologic or lymphoid tissue malignancies. 
 
Table 3. Germline pathogenic mutation and studies on cancer susceptibility 
Confirmed germline variants: 
Gene, variants, zygosity 
Interpretation of 




# case in 
this study 




Studies on monoallelic variant and 




Pathogenic: PVS1, PP3 0.0152 3 5.39 (1.65-17.61), 
P = 0.0053 
AR E Theodoratou et al, 2010: Monoallelic 
MUTYH mutations are associated with 




PM2, PP3, PP5 




PM2, PP3, PP5 




PM2, PP3, PP5 
0 1 - AR E Barroso et al, 2006: The data indicate 
that a relationship between FANCD2 





PM2, PP3, PP5 




PM2, PP3, PP5 
0 1 - Not known K Heikkinen et al, 2006: There's and 
effect for RAD50 haploinsufficiency on 






0 1 - AR S Ding et al, 2007: There is tumorigenic 
contribution of WRN to breast cancer 
development [28]. 
M Wirtenberger et al, 2006: WRN act as 
low-penetrance familial breast cancer 
susceptibility genes [29]. 
a Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and 
the Association for Molecular Pathology. 
b Population frequency based on The Genome Aggregation Database (gnomAD) Exome database, East Asian population. 
Abbreviations: AD: autosomal dominant, AR: autosomal recessive, CI: confidence interval, N/A: not available, OR: odds ratio. 
*Autosomal dominant cancer susceptibility gene. 
 
 




Of 39 patients, 24 (61.5%) were CHIP carriers. 
The median age of the CHIP-positive and 
CHIP-negative patients was 62.5 years (Q1Q3; 52.0, 
71.5) and 58.0 years (Q1Q3; 50.5, 64.5), respectively. 
The median follow-up time was 6 months (Q1Q3; 2.0, 
9.5) for the CHIP-positive patients and 22.5 months 
(Q1Q3; 7.5, 41.5) for the CHIP-negative patients. 
Patients who had secondary lymphoid malignancy 
were less likely to have CHIP than those who had 
myeloid malignancy. Seventy-five percent of the 
patients (18 out of 24) with subsequent myeloid 
malignancies had CHIP mutations, which is similar to 
the previous case-control studies where 62–71% of the 
t-MN cases had CHIP mutations [5, 6]. As suggested 
in literature, CHIP caused by cytotoxic therapy is 
associated with high frequencies of mutations in TP53 
and PPM1D [16, 17]. Consistent with this, in our 
study, the two most frequently mutated genes in the 
CHIP-positive cases were TP53 (7/24, 29.2%) and 
PPM1D (5/24, 20.8%) in 7 patients who underwent 
either cytotoxic chemotherapy or radiation therapy. 
Although statistically significant differences were not 
observed between the CHIP-positive and 
CHIP-negative groups with regard to the incidence of 
cardiovascular disease (CVD) owing to the small 
number of cases, out of 6 patients who had CVD, 5 
cases had CHIP mutations. The CHIP mutations in the 
CVD patients included genes such as TET2, ASXL1, 
DNMT3A, and TP53. 
Discussion 
Although the positive rates of pathogenic 
variants are different among the types of cancer and 
the extent of the NGS panel, they are generally 
considered to be around 7.4%~12.6% when using the 
core gene panel and up to 20% when using an 
extended panel with all known cancer susceptibility 
genes[18-21]. The results from our study are 
consistent with previous studies in that pathogenic 
mutations in low to moderate penetrance genes are 
present in t-MN patients. We should note that 
regardless of the mode of inheritance, there are 
previous studies which correlates monoallelic 
mutation and cancer susceptibility (Table 3). A recent 
study investigated the correlation of 16 Fanconi 
anemia (FA)-related genes with myeloid neoplasms, 
including both de novo AML and t-MN [22]. The 
authors suggested that heterozygous carriers of FA 
variants may have increased susceptibility to 
environmental carcinogens and to the DNA- 
damaging action of cytotoxic therapy used to treat 
primary tumors, leading to de novo or secondary 
leukemogenesis [22]. In the current study, 1 patient 
out of 18 t-MN patients (5.6%) had a germline 
mutation in the FANCD2 gene (NM_033084.3: 
c.757C>T, p.Arg253*). The mutation was reported as 
‘pathogenic’ in FA patients with a severe phenotype 
and has been associated with an increased risk of 
intraductal papillary mucinous neoplasms [23]. The 
FANCD2 protein plays a key role in the initiation of 
the FA pathway, a DNA damage repair mechanism. 
FANCD2 deficiency can lead to uncontrolled cell 
proliferation, leading to FA-associated malignancies, 
and therefore increase cancer susceptibility 
sporadically in the general population [24, 25]. 
The monoallelic (heterozygous) MUTYH 
mutation (NM_001128425.1:c.934-2A>G) was found in 
three patients in this study group. According to the 
gnomAD Exomes database (https://gnomad. 
broadinstitute.org/), this specific splicing mutation 
has a minor allele frequency of 1.5% in the East Asian 
population, which is lower than the incidence rate 
observed in our study group (7.7%, 3/39). Biallelic 
and monoallelic MUTYH mutations are known to be 
associated with increased risk of colorectal cancer 
(CRC) [26, 30] as well as gastric cancer, hepatobiliary 
cancer, endometrial cancer, and breast cancer [31]. 
Out of 15 patients, 4 (26.6%) with subsequent mature 
B-cell neoplasms had germline pathogenic mutations 
in cancer susceptibility genes; MUTYH and WRN in 2 
subsequent DLBCL patients and RAD50 and LZTR1 in 
2 subsequent PCM patients. Besides RAD50, which is 
suggested to have an influence on susceptibility to 
DLBCL [32], MUTYH, WRN, and LZTR1 have never 
been reported to have associations with lymphoid 
malignancies. We showed that monoallelic mutations 
in the genes involved in the DNA damage response 
pathways might be associated with various types of 
cancer, including both de novo and therapy-related 
hematologic malignancies, either from myeloid or 
lymphoid origins. The high prevalence of mutations 
in cancer susceptibility genes in our study group 
indicates the importance of genetic testing in patients 
with primary solid cancers for the risk assessment of 
secondary hematologic malignancies. Indeed, a recent 
study involving long-term childhood cancer survivors 
showed significantly increased rates of subsequent 
neoplasms among carriers of pathogenic mutations in 
DNA repair genes [33]. 
An increased risk of a second primary 
malignancy after RAIT was proposed in several 
studies [34-36], and a recent analysis suggested that 
RAIT is associated with an increased risk of AML and 
chronic myeloid leukemia but not of malignancies of 
the lymphoid tissue or of PCM [37]. Our study results 
also indicate that RAIT is associated with secondary 
myeloid malignancies. Given the fact that age is the 
most relevant factor for CHIP existence [38, 39], our 
result that six out of ten RAIT-treated patients (60%), 
whose average age was 50, showing CHIP positivity 




suggests that CHIP is associated with RAIT. This 
reinforces the result from the previous study [15], 
which was limited by an older-aged cohort 
composition. Although the CHIP analysis in our 
study was performed at the diagnosis of the second 
malignancy, the current understanding of the 
multistep pathogenesis of cancer suggests that 
individuals with clonal mutations may have already 
had smaller clones of existing mutations and they 
were in the path toward the evolution of the 
malignancy [40]. In this context, thyroid cancer 
patients who are candidates for adjuvant RAIT could 
benefit from molecular testing of the hereditary 
cancer NGS panel before treatment. Furthermore, 
monitoring the CHIP composition before and after 
treatment could help with the early detection of 
therapy-related hematologic malignancies. Upon 
further confirmation of this suggestion by 
well-designed studies, more patients will benefit from 
avoiding unnecessary adjuvant RAIT, leading to 
improved overall survival. 
Reports on the association between CHIP and 
chemotherapy-subsequent lymphoid malignancies 
are rare. While the risk of t-MN is known to be higher 
when lymphoma patients with CHIP undergo 
autologous stem cell transplant [41], the risk of the 
development of mature B-cell neoplasms in patients 
with CHIP who undergo chemotherapy or 
radiotherapy against primary solid cancers is not 
widely studied. In our study, 40% (6 out of 15) of the 
patients with subsequent mature B-cell neoplasms 
had CHIP mutations. Unlike t-MN patients with 
CHIP most commonly involving TP53 and PPM1D, a 
variety of genes were observed in the patients with 
lymphoid tissue malignancies: DNMT3A, a DNA 
methyltransferase; EXH2 and KMT2D, which are 
involved in histone modification; CREBBP, which is 
involved in the p53-dependent signal pathways; 
KRAS and BRAF, with roles in the RAS/MAPK 
pathway; and STAT3, which plays a role in cell 
proliferation. Further investigations with age- 
matched controls are needed to reveal the true 
associations between CHIP and therapy-related 
lymphoid tissue malignancies. 
Our study is limited by small number of study 
population, retrospective sample collection and the 
lack of age-matched healthy control. Large-scaled 
prospective study in cancer patient with concurrent or 
subsequent hematologic malignancies should be done 
to add statistical and clinical robustness to the current 
study. 
Conclusions 
In patients with primary solid cancer who are 
planning to undergo cytotoxic chemotherapy, 
radiotherapy, or RAIT, initial assessment with 
germline mutation testing using an expanded NGS 
panel comprising low-, moderate-, and high-risk 
cancer-associated genes and somatic CHIP mutation 
testing can give clue to the patients who are at risk of 
developing therapy-related myeloid and lymphoid 
malignancies. Through careful screening and 
monitoring throughout the treatment process, 
patients may benefit from the early detection of 
secondary malignancies and receive proper treatment. 
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